Clinical trial
A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma
NCT00004066 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 1999
- Completion date
- October 31, 2003
- Enrollment
- 82 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ovarian cancer, sarcoma, small intestine cancer